Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
This study will examine the impacts of two different methods of managing MS-related spasticity of the lower limbs. Both interventions will be presented via video teleconference in group classes consisting of exercises to reduce spasticity.
Description: Impact of spasticity will be measured using the Multiple Sclerosis Spasticity Scale-88 at one month post intervention.
Measure: Impact of spasticity, measured by the Multiple Sclerosis Spasticity Scale-88 Time: One month post-interventionDescription: Severity of spasticity will be measured using the Numeric Rating Scale for Spasticity at one month post intervention.
Measure: Severity of spasticity, measured by the Numeric Rating Scale for Spasticity Time: One month post-interventionDescription: Fatigue will be measured using the Modified Fatigue Impact Scale at one month post intervention.
Measure: Fatigue, measured by the Modified Fatigue Impact Scale Time: One month post-interventionDescription: Sleep quality and quantity will be measured using Pittsburgh Sleep Quality Index at one month post intervention.
Measure: Sleep quality and quantity, measured by the Pittsburge Sleep Quality Index Time: One month post-interventionDescription: Impact on day-to-day life, measured by the Multiple Sclerosis Impact Scale-29 at one month post intervention.
Measure: Impact on day-to-day life, measured by the Multiple Sclerosis Impact Scale-29 Time: One month post-interventionDescription: Emotional Distress - Depression will be measured using PROMIS Item Bank v1.0 - Emotional Distress - Depression-Short Form 8a at one month post intervention.
Measure: PROMIS Item Bank v1.0 - Emotional Distress - Depression-Short Form 8a Time: One month post-interventionDescription: Impact on multiple sclerosis on walking, measured by the Multiple Sclerosis Walking Scale-12 at one month post intervention.
Measure: Impact on multiple sclerosis on walking, measured by the Multiple Sclerosis Walking Scale-12 Time: One month post-interventionDescription: Walking will be measured using the Timed 25 Foot Walk at one month post intervention, only if visit is in person.
Measure: Walking measured by the Timed 25 Foot Walk Time: One month post-interventionDescription: Walking and turning measured by the Timed Up and Go will be measured at one month post intervention, only if visit is in person.
Measure: Walking and turning measured by the Timed Up and Go Time: One month post-interventionDescription: Pain severity and interference measured by a modified version of the Brief Pain Inventory at one month post intervention.
Measure: Pain severity and interference Time: One month post interventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports